Identification of SNPs in the cystic fibrosis interactome influencing pulmonary progression in cystic fibrosis

European Journal of Human Genetics

Volumn 21, Issue 4, 2013, Pages 397-403

  Gisler, Franziska M ^a   Von Kanel, Thomas ^a   Kraemer, Richard ^a   Schaller, André ^a   Gallati, Sabina ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

cystic fibrosis; interactome; modifier genes

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; SYNAPTOSOMAL ASSOCIATED PROTEIN 23;

ADOLESCENT; ADULT; AIRWAY RESISTANCE; ALLELE; ARTICLE; CHILD; CYSTIC FIBROSIS; DISEASE COURSE; FEMALE; FORCED EXPIRATORY VOLUME; GENE FREQUENCY; GENE FUNCTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; INTERACTOME; LUNG CLEARANCE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MODIFIER GENE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; CHILD; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DISEASE PROGRESSION; EPISTASIS, GENETIC; FEMALE; GENE EXPRESSION; HOMOZYGOTE; HUMANS; KERATIN-19; LUNG; LUNG VOLUME MEASUREMENTS; MALE; MODELS, GENETIC; PHOSPHOPROTEIN PHOSPHATASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN PHOSPHATASE 2; QB-SNARE PROTEINS; QC-SNARE PROTEINS;

EID: 84875056614     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2012.181     Document Type: Article

References (48)

1. Riordan JR, Rommens JM, Kerem B et al: Identification of the cystic fibrosisgene: cloning and characterization of complementary DNA. Science 1989; 245:1066-1073. (Pubitemid 19231814)
2. Kerem B, Rommens JM, Buchanan JA et al: Identification of the cystic fibrosis gene:genetic analysis. Science 1989; 245: 1073-1080. (Pubitemid 19231815)
3. Collins FS: Cystic fibrosis: molecular biology and therapeutic implications. Science1992; 256: 774-779.
4. Rosenstein BJ, Cutting GR: The diagnosis of cystic fibrosis: a consensus statement.Cystic Fibrosis Foundation Consensus Panel. J Pediatr 1998; 132: 589-595. (Pubitemid 28194575)
5. Knowles MR, Durie PR: What is cystic fibrosis? N Engl J Med 2002; 347: 439-442. (Pubitemid 34851838)
6. Corey M, Edwards L, Levison H, Knowles M: Longitudinal analysis of pulmonaryfunction decline in patients with cystic fibrosis. J Pediatr 1997; 131: 809-814. (Pubitemid 28027602)
7. Gustafsson PM, Aurora P, Lindblad A: Evaluation of ventilation maldistribution as anearly indicator of lung disease in children with cystic fibrosis. Eur Respir J 2003; 22:972-979. (Pubitemid 37540651)
8. Kraemer R, Blum A, Schibler A, Ammann RA, Gallati S: Ventilation inhomogeneities inrelation to standard lung function in patients with cystic fibrosis. AmJ Respir Crit CareMed 2005; 171: 371-378. (Pubitemid 40223405)
9. Kraemer R, Baldwin DN, Ammann RA, Frey U, Gallati S: Progression of pulmonaryhyperinflation and trapped gas associated with genetic and environmental factors inchildren with cystic fibrosis. Respir Res 2006; 7: 138.
10. Kraemer R, Latzin P, Pramana I, Ballinari P, Gallati S, Frey U: Long-term gas exchangecharacteristics as markers of deterioration in patients with cystic fibrosis. Respir Res2009; 10: 106.
11. Aurora P, Bush A, Gustafsson P et al: Multiple-breath washout as a marker of lungdisease in preschool children with cystic fibrosis. Am J Respir Crit Care Med 2005;171: 249-256.
12. Kraemer R, Birrer P, Liechti-Gallati S: Genotype-phenotype association in infants withcystic fibrosis at the time of diagnosis. Pediatr Res 1998; 44: 920-926. (Pubitemid 28543980)
13. Ranganathan SC, Stocks J, Dezateux C et al: The evolution of airway function in earlychildhood following clinical diagnosis of cystic fibrosis. Am J Respir Crit Care Med2004; 169: 928-933. (Pubitemid 38457319)
14. Konstan MW, Hilliard KA, Norvell TM, Berger M: Bronchoalveolar lavage findings incystic fibrosis patients with stable, clinically mild lung disease suggest ongoinginfection and inflammation. Am J Respir Crit Care Med 1994; 150: 448-454. (Pubitemid 24252357)
15. Ranganathan SC, Dezateux C, Bush A et al: Airway function in infants newly diagnosedwith cystic fibrosis. Lancet 2001; 358: 1964-1965. (Pubitemid 34072881)
16. Vanscoy LL, Blackman SM, Collaco JM et al: Heritability of lung disease severity incystic fibrosis. Am J Respir Crit Care Med 2007; 175: 1036-1043. (Pubitemid 46741755)
17. Buranawuti K, Boyle MP, Cheng S et al: Variants in mannose-binding lectin andtumour necrosis factor alpha affect survival in cystic fibrosis. J Med Genet 2007; 44:209-214. (Pubitemid 46580531)
18. Bremer LA, Blackman SM, Vanscoy LL et al: Interaction between a novel TGFB1haplotype and CFTR genotype is associated with improved lung function in cysticfibrosis. Hum Mol Genet 2008; 17: 2228-2237. (Pubitemid 351916579)
19. Gu Y, Harley IT, Henderson LB et al: Identification of IFRD1 as a modifier gene forcystic fibrosis lung disease. Nature 2009; 458: 1039-1042.
20. Hillian AD, Londono D, Dunn JM et al: Modulation of cystic fibrosis lung disease byvariants in interleukin-8. Genes Immun 2008; 9: 501-508.
21. Darrah R, McKone E, O'Connor C et al: EDNRA variants associate with smooth musclemRNA levels, cell proliferation rates, and cystic fibrosis pulmonary disease severity.Physiol Genomics 2010; 41: 71-77.
22. Wright FA, Strug LJ, Doshi VK et al: Genome-wide association and linkage identifymodifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2.Nat Genet 2011; 43: 539-546.
23. Cormet-Boyaka E, Di A, Chang SY et al: CFTR chloride channels are regulatedby a SNAP-23/syntaxin 1A complex. Proc Natl Acad Sci USA 2002; 99:12477-12482.
24. Tang BL, Gee HY, Lee MG: The cystic fibrosis transmembrane conductance regulator'sexpanding SNARE interactome. Traffic 2011; 12: 364-371.
25. Le Drevo MA, Benz N, Kerbiriou M et al: Annexin A5 increases the cell surfaceexpression and the chloride channel function of the DeltaF508-cystic fibrosistransmembrane regulator. Biochim Biophys Acta 2008; 1782: 605-614.
26. Faria D, Dahimene S, Alessio L et al: Effect of Annexin A5 on CFTR: regulated traffic orscaffolding? Mol Membr Biol 2011; 28: 14-29.
27. Luo J, Pato MD, Riordan JR, Hanrahan JW: Differential regulation of singleCFTR channels by PP2C, PP2A, and other phosphatases. Am J Physiol 1998; 274:C1397-C1410.
28. Thelin WR, Kesimer M, Tarran R et al: The cystic fibrosis transmembrane conductanceregulator is regulated by a direct interaction with the protein phosphatase 2A. J BiolChem 2005; 280: 41512-41520. (Pubitemid 41832212)
29. Vastiau A, Cao L, Jaspers M et al: Interaction of the protein phosphatase 2A with theregulatory domain of the cystic fibrosis transmembrane conductance regulatorchannel. FEBS Lett 2005; 579: 3392-3396. (Pubitemid 40800287)
30. Rotin D, Staub O: Role of the ubiquitin system in regulating ion transport. PflugersArch 2011; 461: 1-21.
31. Caohuy H, Jozwik C, Pollard HB: Rescue of DeltaF508-CFTR by the SGK1/Nedd4-2signaling pathway. J Biol Chem 2009; 284: 25241-25253.
32. Myerburg MM, McKenna EE, Luke CJ, Frizzell RA, Kleyman TR, Pilewski JM: Prostasinexpression is regulated by airway surface liquid volume and is increased in cysticfibrosis. Am J Physiol Lung Cell Mol Physiol 2008; 294: L932-L941.
33. Koulov AV, Lapointe P, Lu B et al: Biological and structural basis for Aha1 regulation ofHsp90 ATPase activity in maintaining proteostasis in the human disease cysticfibrosis. Mol Biol Cell 2010; 21: 871-884.
34. Harada K, Okiyoneda T, Hashimoto Y et al: Calreticulin negatively regulates the cellsurface expression of cystic fibrosis transmembrane conductance regulator. J BiolChem 2006; 281: 12841-12848. (Pubitemid 43855377)
35. Salas PJ, Rodriguez ML, Viciana AL, Vega-Salas DE, Hauri HP: The apical submembranecytoskeleton participates in the organization of the apical pole in epithelial cells.J Cell Biol 1997; 137: 359-375. (Pubitemid 27181290)
36. Sun F: Poster Session Abstracts. Pediatric Pulmology 2009; 44: 213-435.
37. Kraemer R, Meister B: Fast real-time moment-ratio analysis of multibreath nitrogenwashout in children. J Appl Physiol 1985; 59: 1137-1144. (Pubitemid 16192213)
38. Kraemer R, Zehnder M, Meister B: Intrapulmonary gas distribution in healthy children.Respir Physiol 1986; 65: 127-137. (Pubitemid 16045758)
39. Zapletal A, Samanek M, Paul T: Lung function in Children and Adolescents: Methods,Reference Values. Basel: Karger, 1987.
40. Liechti-Gallati S, Schneider V, Neeser D, Kraemer R: Two buffer PAGE systembasedSSCP/HD analysis: a general protocol for rapid and sensitive mutation screeningin cystic fibrosis and any other human genetic disease. Eur J Hum Genet 1999; 7:590-598. (Pubitemid 29378036)
41. Excoffier L, Lischer HE: Arlequin suite ver 3.5: a new series of programs to performpopulation genetics analyses under Linux and Windows. Mol Ecol Resour 2010; 10:564-567.
42. Adzhubei IA, Schmidt S, Peshkin L et al: A method and server for predicting damagingmissense mutations. Nat Methods 2010; 7: 248-249.
43. Ng PC, Henikoff S: Predicting deleterious amino acid substitutions. Genome Res2001; 11: 863-874. (Pubitemid 32447869)
44. Desmet FO, Hamroun D, Lalande M, Collod-Beroud G, Claustres M, Beroud C: HumanSplicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic AcidsRes 2009; 37: e67.
45. Piva F, Giulietti M, Burini AB, Principato G: SpliceAid 2: a database of humansplicing factors expression data and RNA target motifs. Hum Mutat 2012; 33:81-85.
46. Sharma M, Benharouga M, Hu W, Lukacs GL: Conformational and temperaturesensitivestability defects of the delta F508 cystic fibrosis transmembrane conductanceregulator in post-endoplasmic reticulum compartments. J Biol Chem 2001;276: 8942-8950.
47. de Moor CH, Meijer H, Lissenden S: Mechanisms of translational control by the 3' UTRin development and differentiation. Semin Cell Dev Biol 2005; 16: 49-58. (Pubitemid 40126876)
48. Skoko N, Baralle M, Buratti E, Baralle FE: The pathological splicing mutationc.6792C4G in NF1 exon 37 causes a change of tenancy between antagonisticsplicing factors. FEBS Lett 2008; 582: 2231-2236.